JK Lakshmi Cements Ltd. | Q3FY24 | Q3FY23 | YoY (%) | Q2FY24 | QoQ (%) | Institutional Equity Research | CEBPL Est. Dev. (%) |
---|---|---|---|---|---|---|---|
Revenues (INR mn) | 15,861 | 14,885 | 6.6 | 14,526 | 9.2 | 16,155 | (1.8) |
RM Cost | 2,618 | 2,461 | 6.3 | 2,196 | 19.2 | 2,509 | |
Power and Fuel Cost | 3,272 | 4,345 | -24.7 | 3,476 | (5.9) | 3,660 | |
Freight Exp. | 3,131 | 2,942 | 6.4 | 2,848 | 10.0 | 3,094 | |
EBITDA (INR mn) | 2,424 | 1,596 | 51.9 | 1,785 | 35.8 | 2,066 | 17.3 |
EBITDA Margins (%) | 15.3 | 10.7 | 456 bps | 12.3 | 299 bps | 12.8 | 249.0 |
Depreciation | 514 | 480 | 7.0 | 476 | 8.0 | 545 | |
EBIT (INR mn) | 2,080 | 1,272 | 63.6 | 1,460 | 42.5 | 1,716 | 21.3 |
EBIT Margin (%) | 13.1 | 8.5 | 457 bps | 10.1 | 306 bps | 10.6 | 250 bps |
Other Income | 171 | 156 | 9.3 | 151 | 13.1 | 194 | |
Interest | 206 | 247 | -16.8 | 228 | (9.9) | 248 | |
PBT | 1875 | 1,025 | 83.0 | 1,232 | 52.1 | 1468 | |
Tax | 635 | 289 | 119.7 | 402 | 57.9 | 374 | |
PAT (INR mn) | 1,240 | 736 | 68.5 | 830 | 49.4 | 1,094 | 13.4 |
Basic EPS (INR) | 10.5 | 6.3 | 68.5 | 7.1 | 49.4 | 9.3 | 13.4 |
Source: Company, CEBPL
Invest in best pharma mutual funds in India for 2020 with Investica. Explore our top recommended pharma mutual funds to start investing today.